FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028772142> ?p ?o ?g. }

• W3028772142 abstract "Abstract Background The use of recombinant human follicle-stimulating hormone (r-hFSH) in ovarian stimulation protocols for infertility treatment in assisted reproductive technology (ART) clinical practice is well established. More recent advancements include the availability of biosimilar r-hFSH products, which expand the choices available to healthcare practitioners and patients. Better understanding of how such a product contributes to routine clinical practice is valuable to help prescribers make informed treatment choices. The objective of this study was to examine the effectiveness and safety of ovarian stimulation (OS) with follitropin alfa (Ovaleap®) for routine IVF or intracytoplasmic sperm injection treatment in gonadotropin-releasing hormone (GnRH) antagonist cycles in real-world ART clinical practice. Methods This non-interventional, multicenter, prospective study was initiated in 34 specialized reproductive medicine centers in Germany. Eligible women were 18–40 years old with a body mass index < 30 kg/m 2 , menstrual cycle 24–35 days and anti-Müllerian hormone ≥1 ng/mL, who were undergoing a first OS cycle exclusively with Ovaleap® during routine ART using a GnRH antagonist protocol. Primary effectiveness outcomes were number of retrieved oocytes after OS and clinical pregnancy rate (CPR). Secondary outcomes included fertilization rate, number of transferred embryos, live birth delivery rate, safety, and user satisfaction with the Ovaleap® pen. Result(s) Of 507 women screened, 463 received at least 1 dose of Ovaleap® and 439 had Visit 2 data (per protocol population; PPP). The mean(±SD) number of retrieved oocytes was 11.8 ± 7.2 (PPP). The CPR among women with documented embryo transfer was 41.3% (158/383), resulting in a live birth delivery rate of 31.6% (138/437) among PPP patients with available follow-up information. Overall, 8.6% (40/463) of women reported ≥1 adverse drug reaction. Ovarian hyperstimulation syndrome occurred in 23 (5.0%) patients, rated mild in 14 (3.0%), moderate in 8 (1.7%), and severe in 1 (0.2%). Patients reported high user satisfaction and high convenience with use of the Ovaleap® pen. Conclusion The effectiveness and safety of OS with Ovaleap® in a GnRH antagonist protocol were extended to real-world ART clinical practice for the first time. Trial registration Registered on 22 June 2016 (retrospectively registered) at ClinicalTrials.gov ( NCT02809989 )." @default.
• W3028772142 created "2020-06-05" @default.
• W3028772142 creator A5003566413 @default.
• W3028772142 creator A5034741163 @default.
• W3028772142 creator A5071017861 @default.
• W3028772142 creator A5085573506 @default.
• W3028772142 creator A5088012724 @default.
• W3028772142 date "2020-05-26" @default.
• W3028772142 modified "2023-10-14" @default.
• W3028772142 title "Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study" @default.
• W3028772142 cites W1540299321 @default.
• W3028772142 cites W1803355749 @default.
• W3028772142 cites W1941922500 @default.
• W3028772142 cites W1990556789 @default.
• W3028772142 cites W2004054496 @default.
• W3028772142 cites W2036243110 @default.
• W3028772142 cites W2070093506 @default.
• W3028772142 cites W2072858756 @default.
• W3028772142 cites W2102259585 @default.
• W3028772142 cites W2105639953 @default.
• W3028772142 cites W2117334105 @default.
• W3028772142 cites W2118329020 @default.
• W3028772142 cites W2121430100 @default.
• W3028772142 cites W2122112270 @default.
• W3028772142 cites W2126549090 @default.
• W3028772142 cites W2137784415 @default.
• W3028772142 cites W2138598305 @default.
• W3028772142 cites W2142041796 @default.
• W3028772142 cites W2144601959 @default.
• W3028772142 cites W2154661858 @default.
• W3028772142 cites W2186137870 @default.
• W3028772142 cites W2228325863 @default.
• W3028772142 cites W2326748274 @default.
• W3028772142 cites W2414366951 @default.
• W3028772142 cites W2558449694 @default.
• W3028772142 cites W2604742725 @default.
• W3028772142 cites W2605998378 @default.
• W3028772142 cites W2607753478 @default.
• W3028772142 cites W2621363976 @default.
• W3028772142 cites W2734470509 @default.
• W3028772142 cites W2890033634 @default.
• W3028772142 cites W2891240559 @default.
• W3028772142 cites W2969775815 @default.
• W3028772142 cites W2978946677 @default.
• W3028772142 cites W4243576784 @default.
• W3028772142 cites W4256057013 @default.
• W3028772142 doi "https://doi.org/10.1186/s12958-020-00610-2" @default.
• W3028772142 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7251873" @default.
• W3028772142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32456636" @default.
• W3028772142 hasPublicationYear "2020" @default.
• W3028772142 type Work @default.
• W3028772142 sameAs 3028772142 @default.
• W3028772142 citedByCount "6" @default.
• W3028772142 countsByYear W30287721422021 @default.
• W3028772142 countsByYear W30287721422022 @default.
• W3028772142 countsByYear W30287721422023 @default.
• W3028772142 crossrefType "journal-article" @default.
• W3028772142 hasAuthorship W3028772142A5003566413 @default.
• W3028772142 hasAuthorship W3028772142A5034741163 @default.
• W3028772142 hasAuthorship W3028772142A5071017861 @default.
• W3028772142 hasAuthorship W3028772142A5085573506 @default.
• W3028772142 hasAuthorship W3028772142A5088012724 @default.
• W3028772142 hasBestOaLocation W30287721421 @default.
• W3028772142 hasConcept C126322002 @default.
• W3028772142 hasConcept C2776210078 @default.
• W3028772142 hasConcept C2776537878 @default.
• W3028772142 hasConcept C2776659692 @default.
• W3028772142 hasConcept C2777688143 @default.
• W3028772142 hasConcept C2778278907 @default.
• W3028772142 hasConcept C2778279030 @default.
• W3028772142 hasConcept C2779234561 @default.
• W3028772142 hasConcept C2781065240 @default.
• W3028772142 hasConcept C2908647359 @default.
• W3028772142 hasConcept C29456083 @default.
• W3028772142 hasConcept C2994278967 @default.
• W3028772142 hasConcept C500014431 @default.
• W3028772142 hasConcept C512716672 @default.
• W3028772142 hasConcept C54355233 @default.
• W3028772142 hasConcept C71924100 @default.
• W3028772142 hasConcept C86803240 @default.
• W3028772142 hasConcept C99454951 @default.
• W3028772142 hasConceptScore W3028772142C126322002 @default.
• W3028772142 hasConceptScore W3028772142C2776210078 @default.
• W3028772142 hasConceptScore W3028772142C2776537878 @default.
• W3028772142 hasConceptScore W3028772142C2776659692 @default.
• W3028772142 hasConceptScore W3028772142C2777688143 @default.
• W3028772142 hasConceptScore W3028772142C2778278907 @default.
• W3028772142 hasConceptScore W3028772142C2778279030 @default.
• W3028772142 hasConceptScore W3028772142C2779234561 @default.
• W3028772142 hasConceptScore W3028772142C2781065240 @default.
• W3028772142 hasConceptScore W3028772142C2908647359 @default.
• W3028772142 hasConceptScore W3028772142C29456083 @default.
• W3028772142 hasConceptScore W3028772142C2994278967 @default.
• W3028772142 hasConceptScore W3028772142C500014431 @default.
• W3028772142 hasConceptScore W3028772142C512716672 @default.
• W3028772142 hasConceptScore W3028772142C54355233 @default.
• W3028772142 hasConceptScore W3028772142C71924100 @default.
• W3028772142 hasConceptScore W3028772142C86803240 @default.
• W3028772142 hasConceptScore W3028772142C99454951 @default.
• W3028772142 hasIssue "1" @default.

• next